- Email: [email protected]
Dydrogesterone—A unique progestogen
Maturitas 65S (2009) S1
Contents lists available at ScienceDirect
Maturitas journal homepage: www.elsevier.com/locate/maturitas
Preface
Dydrogesterone—A unique progestogen夽
The European Progestogen Club (EPC) was founded in 1996. The 12th working session of the EPC was held in conjunction with the 8th European Congress on the Menopause (EMAS) in London on 21 May 2009. The main topics presented in this issue are based upon the progestogen, dydrogesterone. This molecule is, compared to natural progesterone, 10–20 times more potent, since all the metabolites of dydrogesterone do not lose their progestogenic activity in contrast to progesterone. Dydrogesterone is, compared with other progestogens, devoid of estrogenic, androgenic and glucocorticoid activity. Also dydrogesterone cannot be converted to estrogens like the 19-nortestosterone derivatives. Overall, it does not exhibit unwanted metabolic side effects. Therefore, dydrogesterone is a suitable progestogen to be used clinically throughout a women’s life time both during and outside pregnancy. Its use will be detailed in the papers selected for the issue. Besides the favourable progestogenic effects on the endometrium, there are two articles on dydrogesterone and the breast. Benign lesions such as endometriosis and adenomyosis, as well as bleeding disorders are discussed. In view of the ongoing controversies regarding progestogens in hormone replacement therapy the article on the menopause is clinically of the utmost importance.
夽 Date and venue of symposium: 21/05/09 in London. 0378-5122/$ – see front matter © 2009 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.maturitas.2009.09.002
It is also relevant that luteal support in connection with the first trimester of pregnancy regarding threatened and recurrent abortion – a still relatively neglected clinical issue particularly as women are deferring pregnancy to later in life – will also be discussed. Conflict of interest There is no actual or potential conflict of interest. Guest Editor Adolf E. Schindler (MD, PhD) ∗ Institute for Medical Research and Education, Hufelandstr. 55, 45122 Essen, Germany ∗ Tel.:
+49 201 7991833; fax: +49 201 7499533. E-mail addresses: [email protected], [email protected], [email protected] 3 September 2009
Contents lists available at ScienceDirect
Maturitas journal homepage: www.elsevier.com/locate/maturitas
Preface
Dydrogesterone—A unique progestogen夽
The European Progestogen Club (EPC) was founded in 1996. The 12th working session of the EPC was held in conjunction with the 8th European Congress on the Menopause (EMAS) in London on 21 May 2009. The main topics presented in this issue are based upon the progestogen, dydrogesterone. This molecule is, compared to natural progesterone, 10–20 times more potent, since all the metabolites of dydrogesterone do not lose their progestogenic activity in contrast to progesterone. Dydrogesterone is, compared with other progestogens, devoid of estrogenic, androgenic and glucocorticoid activity. Also dydrogesterone cannot be converted to estrogens like the 19-nortestosterone derivatives. Overall, it does not exhibit unwanted metabolic side effects. Therefore, dydrogesterone is a suitable progestogen to be used clinically throughout a women’s life time both during and outside pregnancy. Its use will be detailed in the papers selected for the issue. Besides the favourable progestogenic effects on the endometrium, there are two articles on dydrogesterone and the breast. Benign lesions such as endometriosis and adenomyosis, as well as bleeding disorders are discussed. In view of the ongoing controversies regarding progestogens in hormone replacement therapy the article on the menopause is clinically of the utmost importance.
夽 Date and venue of symposium: 21/05/09 in London. 0378-5122/$ – see front matter © 2009 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.maturitas.2009.09.002
It is also relevant that luteal support in connection with the first trimester of pregnancy regarding threatened and recurrent abortion – a still relatively neglected clinical issue particularly as women are deferring pregnancy to later in life – will also be discussed. Conflict of interest There is no actual or potential conflict of interest. Guest Editor Adolf E. Schindler (MD, PhD) ∗ Institute for Medical Research and Education, Hufelandstr. 55, 45122 Essen, Germany ∗ Tel.:
+49 201 7991833; fax: +49 201 7499533. E-mail addresses: [email protected], [email protected], [email protected] 3 September 2009